Towards Healthcare
Cell And Gene Therapy Manufacturing Market leads 16.25% CAGR by 2034

Cell And Gene Therapy Manufacturing Market to Hit $22.88 Bn by 2034

The cell and gene therapy manufacturing market size is calculated at $5.9 bn in 2025 is to hit $22.88 bn by 2034. In 2024, North America led the cell and gene therapy manufacturing market, with Asia-Pacific expected to grow the fastest. Allogeneic cell therapy, somatic cell technology, and induced pluripotent stem cells dominated the market. Musculoskeletal applications held the largest market share.

The cell and gene therapy manufacturing market size is estimated to be USD 5.08 billion in 2024 to reach an estimate of USD 22.88 billion by 2034, at a 16.25% CAGR between 2025 to 2034. The burgeoning biotechnology sector, growing cell and gene therapy research, and increasing investments drive the market.

Cell and Gene Therapy Manufacturing Market Size 2023 - 2034

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Highlights of the Cell and Gene Therapy Manufacturing Market

  • North America dominated the cell and gene therapy manufacturing market in 2024.
  • Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
  • By therapy, the allogeneic cell therapy segment held a dominant presence in the market in 2024.
  • By technology, the somatic cell technology segment led the global market in 2024.
  • By source, the induced pluripotent stem cells segment registered its dominance over the global market in 2024.
  • By application, the musculoskeletal segment held the largest share of the market in 2024.

Cell and Gene Therapy Manufacturing Market Overview

Cell and gene therapy manufacturing is a specialized process that produces cell and gene therapy (CGT) products on a large scale. It requires advanced facilities, equipment, and expertise. Cell therapy involves transplanting cells into a patient to replace or repair damaged tissue, and gene therapy involves inserting, deleting, or modifying genes in a patient’s cells to treat or prevent disease. Both cell and gene therapy products undergo different manufacturing processes. Steps involved in cell therapy manufacturing are sourcing and isolation of cells, activation, and genetic modification, and expansion and culture. The steps involved in gene therapy manufacturing are viral vector expression, cell growth, harvest of viral vector, and filtration & purification.

Considering its potential to treat cancer, cell and gene therapy has sparked a lot of interest. With a complicated and expanding sector, a Contract Development and Manufacturing Company (CDMO) may assist customers in smoothing commercial cell and gene therapy manufacturing needs.

In August 2022, Cytiva, a subsidiary of Danaher Corporation, and Forecyte Bio, a provider of CDMO service designed for cell gene therapy, collaborated to accelerate the development and manufacturing of cell and gene therapies in China and the U.S. Forecyte Bio will use Cytiva’s Flex Factory platform to launch its contract development and manufacturing organization (CDMO) business.

Cell and Gene Therapy Manufacturing Market Growth Factors

  • Rising Incidences of Chronic Disorders: The rising incidences of chronic disorders, such as cancer, necessitate the development of CGT products, boosting market growth.
  • Burgeoning Biotech Sector: The growing demand for biologicals potentiates the growth of the biotech sector, thereby promoting market growth.
  • Increasing Investments: Several government and private organizations provide funding to promote CGT research and manufacturing.
  • Increasing Number of Clinical Trials: The increasing number of clinical trials on CGT products requires manufacturing these products.

How Can AI Improve the Cell And Gene Therapy Manufacturing Market?

Artificial intelligence (AI) plays a vital role in the manufacturing of CGT products. AI introduces automation in the manufacturing process, overcoming the challenges faced during conventional processes. AI can aid in the large-scale manufacturing of CGT. Automation enhances efficiency and reproducibility, reducing the time and cost of manufacturing. The use of AI and robots is still in its infancy. However, it is favorable for large-scale and homogenous production, reducing variability. Moreover, AI and machine learning (ML) algorithms can be used in R&D to develop novel CGTs. AI and ML can be used to rapidly screen more candidates and select designs that fulfill the desired criteria. AI and ML can also aid in streamlining the supply chain of CGTs, resulting in timely delivery to large consumers.

Survey Shows Growing Optimism in Cell and Gene Therapy Industry:

A recent survey on the cell and gene therapy (CGT) industry reveals that while CGT innovators and healthcare providers have had a positive view of the sector over the past 12–18 months (86% and 83%, respectively), contract development and manufacturing organizations (CDMOs) were less optimistic (66%). Looking forward, optimism increases across all groups for the next 12–18 months, with CGT innovators (93%), healthcare providers (86%), and CDMOs (83%) expecting positive developments. Gene therapies are anticipated to have a more favorable outlook compared to autologous and allogeneic cell therapies.

Market Dynamics

Driver

Burgeoning Biotech Sector

The rapidly expanding biotechnology sector promotes cell and gene therapy manufacturing owing to its growing demand. The increasing number of biotechnology companies is accelerating research and development activities and manufacturing of CGT products. The increasing investment and expanding manufacturing facilities play a major role in expanding the biotech sector. Several institutions and organizations regularly conduct seminars, workshops, and conferences to increase awareness about biotech products and aid in the training of researchers. The increasing number of biotech startups globally also augments market growth. This also leads to the growing research and development activities to develop novel CGTs. The increasing number of FDA-approved therapies fuel the growth of CGT manufacturing.

Opportunity

Growing Demand for Precision Medicine

The growing demand for precision medicine presents future growth opportunities for the cell and gene therapy manufacturing market due to rapidly changing demographics and increasing population. Several government organizations release guidelines and initiatives to support precision medicine development. The government and private organizations also provide funding for precision medicine research. CGT products are the most personalized forms of medicine. Autologous cell therapies and CRISPR-directed gene therapy enable a new era of precision medicine. Moreover, technological advancements in CGT manufacturing facilitate the development of precision medicine.

Restraints

Hurdles Faced During Market Growth

One of the most significant issues is the high cost of cell treatments, which has financial consequences for patients, payers, and providers. As a result, firms must lower their pricing in order to increase the acceptance of these medicines, which is projected to hamper market growth throughout the forecast period.

Market Scope and Categorization of the Cell and Gene Therapy Manufacturing Market

The Allogeneic Cell Therapy Segment Dominated

Cell and Gene Therapy Manufacturing Market Value, By Therapy Type, 2017-2030

The allogeneic cell therapy segment is estimated to be valued at US$ 1,198.2 Mn in 2022 and is expected to reach US$ 3,129.6 Mn by 2030 at a CAGR of 12.8%.

By therapy, the allogeneic cell therapy segment held a dominant presence in the cell and gene therapy manufacturing market in 2023. Allogeneic cell therapy is a process in which the donor’s healthy blood-forming cells (stem cells) are introduced into a patient’s body. Allogeneic stem cells are used to treat one or more patients. They are predominantly used in medical emergencies. They also offer superior advantages over autologous stem cells. Cells from healthy, young donors are derived to reduce the risk of co-morbidities associated with disease states. The latest innovations in the effective storage and availability of these cells in healthcare settings augment the segment’s growth.

The Somatic Cell Technology Segment Led in 2023

Cell and Gene Therapy Manufacturing Market Value, By Technology Type, 2017 & 2030

The somatic cell technology segment is estimated to be valued at US$ 823.2 Mn in 2022 and is expected to reach US$ 2,345.6 Mn by 2030 at a CAGR of 14.0%.

By technology, the somatic cell technology segment led the global cell and gene therapy manufacturing market in 2023. Somatic cell technology is a technique by which the nucleus of a differentiated cell is introduced into an oocyte from which its genetic material has already been removed. This technique allows the development of near-identical genetic copies of valuable animals with known and desirable traits to be reproduced. Stem cells derived from somatic cells can help cure degenerative diseases. The rising incidences of degenerative diseases and advancements in technology promote the segment’s growth.

The Induced Pluripotent Stem Cells Segment Dominated

Cell and Gene Therapy Manufacturing Market Value, By Source, 2017-2030

IPSC’s (Induced pluripotent stem cell) segment is estimated to be valued at US$ 1,092.5 Mn in 2022 and is expected to reach US$ 4,092.3 Mn by 2030 at a CAGR of 17.9%.

By source, the induced pluripotent stem cells segment registered its dominance over the global cell and gene therapy manufacturing market in 2023. Induced pluripotent stem cells (iPSCs) are immature cells derived from adult cells that have the ability to differentiate into any cell type in the body. They are used to model human development and diseases and perform high-throughput drug screening. The rising incidences of neurological and other chronic disorders, increasing investments & collaborations, and technological advancements potentiate the segment’s growth. 

The Musculoskeletal Segment Held the Largest Share

Cell and Gene Therapy Manufacturing Market Value, By Application, 2017-2030

The musculoskeletal segment is estimated to be valued at US$ 807.3 Mn in 2022 and is expected to reach US$ 2,740.2 Mn by 2030 at a CAGR of 16.5%.

By application, the musculoskeletal segment held the largest share of the cell and gene therapy manufacturing market in 2023. The rising incidences and prevalence of musculoskeletal disorders and growing research and development activities boost the segment’s growth. According to the World Health Organization, approximately 1.71 billion globally suffer from musculoskeletal disorders. The growing demand for CGT to treat musculoskeletal disorders also propels the segment’s growth.

Regional Insights

Cell and Gene Therapy Manufacturing Market NA, EU, APAC, LA, MEA Share, 2023 (%)

New Product Launches Dominated North America

North America dominated the cell and gene therapy manufacturing market in 2023. The presence of key players, technological advancements, and favorable government policies drive the market. The U.S. Department of Health and Human Services will launch the Cell and Gene Therapy Access Model in January 2025, inviting drug manufacturers to provide access to CGT products at lower prices. The rising investments in North America also show positive growth in the market. The Government of Canada invested around $2.2 billion from 2020 to 2024 to strengthen domestic biomanufacturing and life sciences capabilities.

  • OmniaBio invested $580 million to build a new biomanufacturing facility in Hamilton, Ontario.

The increasing number of FDA-approved CGT products potentiates market growth. As of December 2024, 41 CGT products have been approved by the U.S. FDA. In 2022, the U.S. FDA approved 12 CGTs, while in 2023, it approved 7 CGT products for different purposes.

Favorable Government Policies Drive Asia-Pacific

Asia-Pacific is anticipated to grow at the fastest rate in the cell and gene therapy manufacturing market during the forecast period. The rising incidences and prevalence of chronic disorders, expanding manufacturing ecosystem, and rising foreign direct investment drive the market. The Chinese government permits foreign investment in CGT and wholly foreign-owned hospitals in selected cities of China. It has also pledged to encourage more research in CGT at the country’s biotech hub in the eastern Chinese city of Suzhou. The Indian Government also supports CGT manufacturing with the growing biotech sector and encourages collaboration to boost market growth.

  • In April 2024, the President of India, Smt. Droupadi Murmu launched India’s first home-grown anti-cancer CAR-T cell therapy, NexCAR19, to increase its accessibility and affordability. The product was developed in collaboration with the Indian Institute of Technology, Bombay, and the Tata Memorial Center.

Latest Announcement by Industry Leaders

Josh Ludwig, Global Director of Global Operations for ScaleReady, commented that, in the future, the focus will shift from autologous to allogeneic approaches with durable responses and eliminate the use of viruses, lentivirus, and retrovirus in favor of nonviral gene editing techniques. This has the potential to reduce costs by providing off-the-shelf varieties of CAR-T therapies.

Recent Developments in the Cell and Gene Therapy Manufacturing Market

  • In October 2024, Cellular Origins and Fresenius Kabi announced a collaboration to integrate the latter’s suite of cell therapy processing technologies within the former’s CGT robotic manufacturing platform, Constellation.
  • In August 2024, PHC Corporation Biomedical Division announced the launch of LiCellGrow, a new cell expansion system, to promote the development of cell and gene therapy products manufacturing process.
  • In May 2024, Merck announced the acquisition of Mirus Bio for $600 million to advance its integrated offering for viral vector manufacturing using Mirus Bio’s transfection reagents.

Cell and Gene Therapy Manufacturing Market Companies

Cell And Gene Therapy Manufacturing Market Top Companies

  • Bluebird Bio Inc.
  • Hitachi Chemical Co., Ltd.
  • Takara Bio Inc.
  • Catalent Inc.
  • F. Hoffmann-La Roche Ltd.
  • Samsung Biologics
  • Novartis AG
  • Lonza
  • Merck KGaA
  • Wuxi Advanced Therapies
  • Boehringer Ingelheim
  • Cellular Therapeutics
  • Miltenyi Biotec
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd
  • Bluebird Bio Inc.

Segments Covered in the Report

By Therapy

  • Allogeneic Cell Therapy
  • Autologous Cell Therapy

By Technology

  • Somatic Cell Technology
  • Cell Immortalization Technology
  • Viral Vector Technology
  • Genome Editing Technology
  • Cell Plasticity Technology
  • 3D Technology

By Source

  • Induced Pluripotent Stem Cells
  • Umbilical Cord
  • Neural Stem
  • Bone Marrow
  • Adipose Tissue

By Application

  • Musculoskeletal
  • Cardiovascular
  • Gastrointestinal
  • Neurological
  • Oncology
  • Dermatology
  • Others

By Region

  • North America
    • US
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Insight Code: 5024
  • No. of Pages: 150
  • Format: PDF/PPT/Excel
  • Last Updated: 31 December 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Rohan Patil is a market research expert with 5+ years of experience in healthcare, specializing in market dynamics, emerging trends, and technology-driven innovations to guide data-driven decisions for healthcare organizations.

Learn more about Rohan Patil

Aditi Shivarkar, with 14+ years of healthcare market research experience, ensures the accuracy, clarity, and relevance of reports. Her expertise helps businesses make informed decisions and stay competitive in healthcare sectors.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

The cell and gene therapy treats a variety of diseases including adenosine deaminase severe combined immunodeficiency (ADA- SCID), congenital blindness, hemophilia, Lebers congenital amaurosis, lysosomal storage diseases, X-linked chronic granulomatous disease, etc.

Cell therapy involves the transfer of cells with desired function into the patient, whereas gene therapy involves the transfer of genetic material in a carrier or vector and the uptake of the gene into targeted cells.

Food and Drug Administration, Government of Canada, Press Information Bureau, Department of Biotechnology, Government of India.